DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair, With death on the horizon, this will not stop me, Only God and death can..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai), INDIA, worlddrugtracker, 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.8 Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution
n, सुकून उतना ही देना प्रभू, जितने से जिंदगी चल जाये।औकात बस इतनी देना,कि औरों का भला हो जाये।...........P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.
Showing posts with label ROSAPROSTOL. Show all posts
Showing posts with label ROSAPROSTOL. Show all posts

Tuesday, 28 July 2015


CAS Registry Number: 56695-65-9
CAS Name: 2-Hexyl-5-hydroxycyclopentaneheptanoic acid
Additional Names: 9-hydroxy-19,20-bisnorprostanoic acid
Manufacturers' Codes: C-83; IBI-C83
Trademarks: Rosal (IBI)
Molecular Formula: C18H34O3
Molecular Weight: 298.46
Percent Composition: C 72.44%, H 11.48%, O 16.08%
Derivative Type: Sodium salt
CAS Registry Number: 56695-66-0
Molecular Formula: C18H33NaO3
Molecular Weight: 320.44
Percent Composition: C 67.47%, H 10.38%, Na 7.17%, O 14.98%
Properties: White solid. LD50 orally in mice: ~3000 mg/kg (Valcavi, 1978); orally in rats: >5 g/kg (Valcavi, 1982).
Toxicity data: LD50 orally in mice: ~3000 mg/kg (Valcavi, 1978); orally in rats: >5 g/kg (Valcavi, 1982)
Therap-Cat: Antiulcerative.



J. Org. Chem. 1998, 63, 8894-8897
Abstract Image
A total synthesis of racemic rosaprostol, an untiulcer drug, has been achieved in seven synthetic steps and in 42% overall yield starting from dimethyl methanephosphonate. The key steps include intramolecular carbenoid cyclization of dimethyl 1-diazo-2-oxoundecanephosphonate 4 leading to 2-dimethoxyphosphoryl-3-hexylcyclopentanone 5 and the Horner−Wittig reaction of the latter with methyl 5-formylpentanecarboxylate 6 employed for the introduction of the methoxycarbonylhexyl moiety at C(2) of the cyclopentanone ring
1 (0.076 g, 95%) as a mixture of trans-trans and trans-cis isomers: Rf ) 0.18 and 0.23 (petroleum ether/Et2O/ AcOH 8:8:0.1);
1H NMR δ 4.19-4.10 (m, 1H), 3.92-3.80 (m, 1H), 2.18 (t, J ) 7.3, 4H), 2.10-1.96 (m, 1H), 1.82-0.85 (m, 51H), 0.93 (t, J ) 6.6, 6H);
13C NMR δ 180.13, 79.93, 75.13, 55.09, 52.71, 45.71, 43.02, 37.15, 36.33, 35.23, 34.95, 34.71, 34.61, 33.03, 30.86, 30.77, 30.69, 30.48, 30.12, 30.03, 29.53, 29.48, 29.21, 28.79, 28.67, 25.68, 23.81, 15.06;
HRMS (CI) (M + H - H2O)+ calcd for C18H33O2 281.2480, obsd 281.2476.


References: Prostaglandin analog. Prepn, hypolipemic, platelet aggregation inhibitory activity: U. Valcavi, DE 2535343,eidem, US 4073938 (1976, 1978 both to Ist. Biochim. Ital.).
Alternate process: V. Marotta, G. Zabban, EP 155392 (1985 to Ist. Biochim. Ital.).
Gastric antisecretory, cytoprotective activity: U. Valcavi et al., Arzneim.-Forsch. 32, 657 (1982).
Effect on mucus and gastrin secretion in duodenal ulcer: D. Foschi et al., Prostaglandins Leukotrienes Med. 15, 147 (1984). Comparison with cimetidine, q.v.: eidem, Drugs Exp. Clin. Res. 10, 427 (1984).
Clinical evaluation in treatment of ulcers: G. P. Tincani et al.,Minerva Med. 78, 847 (1987).